戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 63 for acetylcholine and r=-0.11, P=0.75 for isosorbide dinitrate).
2 t infusions of adenosine, acetylcholine, and isosorbide dinitrate.
3 y and sudden death compared with hydralazine/isosorbide dinitrate.
4  heart failure when given concomitantly with isosorbide dinitrate.
5 d by selective infusion of acetylcholine and isosorbide dinitrate.
6           Finally, an intracoronary bolus of isosorbide dinitrate (1000 microgram) was given.
7 n of hydralazine hydrochloride, 37.5 mg, and isosorbide dinitrate, 20 mg, for treating heart failure
8  not SV dilated in response to adenosine and isosorbide dinitrate (all P<0.05, RA versus SV, percent
9  of treatment with fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patien
10                    Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced m
11 ing enzyme inhibitors and the combination of isosorbide dinitrate and hydralazine differs in black an
12  reported that the fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC
13  with greater impact of fixed combination of isosorbide dinitrate and hydralazine on the primary comp
14     We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional
15 ricle remodeling, outcomes and the impact of isosorbide dinitrate and hydralazine.
16                                              Isosorbide dinitrate and nitroglycerin markedly inhibite
17 ockers, aldosterone antagonists, hydralazine/isosorbide dinitrate, and anticoagulants.
18 03 for acetylcholine and r=-0.62, P=0.05 for isosorbide dinitrate) but not in LITA (r=-0.18, P=0.63 f
19 Although the combined use of hydralazine and isosorbide dinitrate confers important clinical benefits
20              In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart failure with red
21                      Previous trials testing isosorbide dinitrate/hydralazine (I/H) were performed in
22                    Fixed-dose combination of isosorbide dinitrate/hydralazine (ISDN/HYD) improved cli
23  and a fixed dose combination of hydralazine-isosorbide dinitrate in 2005.
24 ts in 24.1% (87.4% of eligible), hydralazine/isosorbide dinitrate in 8.6% (93.1% of eligible), and an
25 sion was also observed in vivo in rats given isosorbide dinitrate in the drinking water, with a dose-
26  overall effect of hydralazine hydrochloride-isosorbide dinitrate in the mostly white patient populat
27 ceived either 100 mg of sildenafil, 10 mg of isosorbide dinitrate (ISDN) or placebo during exercise o
28 creased overall mortality versus hydralazine/isosorbide dinitrate (p < 0.035) in V-HeFT II.
29 in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs.
30 randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addi
31  was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placeb
32              The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therap
33 r in combination with nitroglycerin (NTG) or isosorbide dinitrate restores Ca(2+) cycling and contrac
34 ethylenetriamine-NO and the organic nitrate, isosorbide dinitrate, the inhibitory effects of NO-aspir
35 combination of hydralazine hydrochloride and isosorbide dinitrate was approved by the U.S. Food and D
36 placebo therapy in V-HeFT I, and hydralazine/isosorbide dinitrate was compared with enalapril in V-He
37 on fraction >35%, treatment with hydralazine/isosorbide dinitrate was compared with prazosin and plac
38 w responses to adenosine, acetylcholine, and isosorbide dinitrate were comparable.
39 ions that compared hydralazine hydrochloride-isosorbide dinitrate with placebo or with enalapril.
40 t failure who took hydralazine hydrochloride-isosorbide dinitrate with standard therapy experienced a

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。